Changeflow GovPing Healthcare NSCLC brain metastasis survival prediction meth...
Routine Rule Added Final

NSCLC brain metastasis survival prediction method patent granted

Favicon for changeflow.com USPTO Patent Grants - Diagnosis & Surgery (A61B)
Published
Detected
Email

Summary

USPTO granted patent US12594024B2 on April 7, 2026, to THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a method of predicting survival of non-small cell lung cancer patients with brain metastasis. The patent covers comparing patient TMTrg values against cut-off values for long-term survival prediction using medical imaging analysis.

What changed

USPTO granted patent US12594024B2 to Catholic University of Korea IAC Foundation for a method of predicting survival of non-small cell lung cancer (NSCLC) patients with brain metastasis by comparing patient TMTrg values against cut-off values for long-term survival prediction. The patent (3 claims) covers a diagnostic method involving medical imaging analysis.

Competitors developing cancer diagnostic or survival prediction methods should review this patent for potential IP implications. The granted patent may restrict development of similar survival prediction methods without license, affecting companies in oncology diagnostics and cancer research technology.

What to do next

  1. Monitor for patent landscape implications in cancer diagnostics
  2. Review freedom to operate for survival prediction methods
  3. Consider licensing options if developing similar diagnostic methods

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Method for predicting survival of non small cell lung cancer patients with brain metastasis

Grant US12594024B2 Kind: B2 Apr 07, 2026

Assignee

THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION

Inventors

Seung Ho Yang, Young Il Kim, Hyun Ho Kim

Abstract

The present invention relates to a method for predicting survival of non-small cell lung cancer patients with brain metastasis. More specifically, it proposes a method that is useful for predicting the survival of the patients by comparing TMTrg of the patients with cut off value for predicting long term survival.

CPC Classifications

A61B 5/4519 A61B 5/055 A61B 5/0042 A61B 5/0803 A61B 5/7275 G06T 7/60 G06T 2207/10088 G06T 2207/30016

Filing Date

2024-03-28

Application No.

18620652

Claims

3

View original document →

Get daily alerts for USPTO Patent Grants - Diagnosis & Surgery (A61B)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 7th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12594024B2

Who this affects

Applies to
Medical device makers Healthcare providers Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent portfolio management Cancer diagnostics development Medical imaging analysis
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Medical Devices Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Grants - Diagnosis & Surgery (A61B) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!